Geneva Capital Management LLC Has $56.15 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Key Points

• Geneva Capital Management LLC increased its holdings in Certara, Inc. by 3.9%, acquiring 213,089 shares in the first quarter, bringing its total ownership to 5,671,689 shares valued at $56.15 million.
• Other institutional investors have also adjusted their positions, with notable increases from Versant Capital Management (up 218.8% in Q1) and Wells Fargo (up 48.4% in Q4).
• Analyst ratings for Certara indicate a consensus of "Moderate Buy" with a target price of $15.29, showcasing mixed upgrades and downgrades from various financial institutions.

Geneva Capital Management LLC boosted its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 3.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,671,689 shares of the company's stock after purchasing an additional 213,089 shares during the quarter. Geneva Capital Management LLC owned about 3.51% of Certara worth $56,150,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CERT. ArrowMark Colorado Holdings LLC lifted its position in shares of Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after acquiring an additional 3,861,674 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Certara by 864.0% during the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after acquiring an additional 3,387,590 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Certara during the 4th quarter valued at $17,852,000. Royce & Associates LP bought a new stake in shares of Certara during the 1st quarter valued at $4,439,000. Finally, Gotham Asset Management LLC lifted its position in shares of Certara by 590.1% during the 4th quarter. Gotham Asset Management LLC now owns 431,326 shares of the company's stock valued at $4,594,000 after acquiring an additional 368,821 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Price Performance

CERT traded up $1.73 on Thursday, reaching $11.26. The stock had a trading volume of 3,450,222 shares, compared to its average volume of 1,742,983. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $15.69. The firm has a 50-day moving average of $10.94 and a 200-day moving average of $11.79. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -563.00 and a beta of 1.42.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm had revenue of $104.57 million during the quarter, compared to analyst estimates of $104.14 million. During the same period in the previous year, the company earned $0.07 EPS. Certara's revenue for the quarter was up 12.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CERT shares. KeyCorp dropped their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Morgan Stanley started coverage on Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective for the company. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Finally, Robert W. Baird upped their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.14.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.